PL3118311T3 - Antysensowny kwas nukleinowy - Google Patents

Antysensowny kwas nukleinowy

Info

Publication number: PL3118311T3
Authority: PL; Poland
Prior art keywords: antisensive; nucleic acid; nucleic; acid; antisensive nucleic
Prior art date: 2014-03-12

Application number

PL15761392T

Other languages

English (en)

Inventor

Tatsushi Wakayama

Haruna SEO

Youhei Satou

Shin'ichi Takeda

Tetsuya Nagata

Original Assignee

Nippon Shinyaku Co., Ltd.

National Center Of Neurology And Psychiatry

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-12

Filing date

2015-03-11

Publication date

2019-09-30

2015-03-11 Application filed by Nippon Shinyaku Co., Ltd., National Center Of Neurology And Psychiatry filed Critical Nippon Shinyaku Co., Ltd.

2019-09-30 Publication of PL3118311T3 publication Critical patent/PL3118311T3/pl

Links

150000007523 nucleic acids Chemical class 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL15761392T 2014-03-12 2015-03-11 Antysensowny kwas nukleinowy PL3118311T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2014048897		2014-03-12
PCT/JP2015/057180 WO2015137409A1 (ja)	2014-03-12	2015-03-11	アンチセンス核酸
EP15761392.8A EP3118311B1 (en)	2014-03-12	2015-03-11	Antisense nucleic acid

Publications (1)

Publication Number	Publication Date
PL3118311T3 true PL3118311T3 (pl)	2019-09-30

Family

ID=54071850

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15761392T PL3118311T3 (pl)	2014-03-12	2015-03-11	Antysensowny kwas nukleinowy

Country Status (31)

Country	Link
US (5)	US9988629B2 (pl)
EP (2)	EP3514234A1 (pl)
JP (1)	JP6606488B2 (pl)
KR (1)	KR102335801B1 (pl)
CN (2)	CN106459955B (pl)
AU (2)	AU2015227733B2 (pl)
BR (1)	BR112016020618B1 (pl)
CA (1)	CA2939948A1 (pl)
CY (1)	CY1121322T1 (pl)
DK (1)	DK3118311T3 (pl)
ES (1)	ES2710802T3 (pl)
HR (1)	HRP20190235T1 (pl)
HU (1)	HUE042283T2 (pl)
IL (1)	IL247663B (pl)
LT (1)	LT3118311T (pl)
MX (1)	MX2016011538A (pl)
MY (1)	MY193708A (pl)
NZ (1)	NZ724836A (pl)
PH (1)	PH12016501761B1 (pl)
PL (1)	PL3118311T3 (pl)
PT (1)	PT3118311T (pl)
RS (1)	RS58573B1 (pl)
RU (2)	RU2730681C2 (pl)
SG (1)	SG11201607095RA (pl)
SI (1)	SI3118311T1 (pl)
SM (1)	SMT201900169T1 (pl)
TR (1)	TR201901939T4 (pl)
TW (2)	TW201945383A (pl)
UA (1)	UA120849C2 (pl)
WO (1)	WO2015137409A1 (pl)
ZA (1)	ZA201605864B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2730681C2 (ru) *	2014-03-12	2020-08-24	Ниппон Синяку Ко., Лтд.	Антисмысловые нуклеиновые кислоты
AU2015277924B2 (en)	2014-06-17	2021-02-25	National Center Of Neurology And Psychiatry	Antisense nucleic acids
HRP20201125T1 (hr)	2015-09-15	2020-10-30	Nippon Shinyaku Co., Ltd.	Antisens nukleinska kiselina
EP3359523A4 (en)	2015-10-09	2019-07-24	Wave Life Sciences Ltd.	OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR
KR102775461B1 (ko)	2016-04-01	2025-02-28	어비디티 바이오사이언시스 인크.	핵산-폴리펩타이드 조성물 및 이의 용도
AU2017290231A1 (en)	2016-06-30	2019-02-07	Sarepta Therapeutics, Inc.	Exon skipping oligomers for muscular dystrophy
US20190330626A1 (en) *	2016-07-15	2019-10-31	Ionis Pharmaceuticals, Inc.	Compounds and methods for use in dystrophin transcript
CA3037663A1 (en) *	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified-rna oligonucleotide compositions and uses thereof
LT3554553T (lt)	2016-12-19	2022-08-25	Sarepta Therapeutics, Inc.	Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
CN117298290A (zh)	2016-12-19	2023-12-29	萨勒普塔医疗公司	用于肌肉萎缩症的外显子跳跃寡聚体缀合物
EP3554552B1 (en)	2016-12-19	2022-08-17	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
CN110381980A (zh) *	2017-01-06	2019-10-25	艾维迪提生物科学有限责任公司	核酸-多肽组合物以及诱导外显子跳读的方法
GB201711809D0 (en)	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
EA201991450A1 (ru)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MA49986A (fr)	2017-09-25	2020-07-01	Massachusetts Inst Technology	Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
JP2020536060A (ja)	2017-09-28	2020-12-10	サレプタセラピューティクス，インコーポレイテッド	筋ジストロフィーを処置するための併用療法
IL277889B2 (en)	2018-04-12	2025-01-01	Wave Life Sciences Ltd	Oligonucleotide preparations and methods of using them
SG11202010131QA (en)	2018-05-11	2020-11-27	Wave Life Sciences Ltd	Oligonucleotide compositions and methods of use thereof
US10758629B2 (en)	2018-05-29	2020-09-01	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
US20210346290A1 (en) *	2018-06-13	2021-11-11	Kawasaki Institute Of Industrial Promotion	POLYION COMPLEX MICELLE THAT INCLUDES ANTISENSE OLIGONUCLEOTIDE AND BLOCK COPOLYMER OF PEG BLOCK AND CATIONIC POLYMER, SAID BLOCK COPOLYMER HAVING NUMBER-AVERAGE MOLECULAR WEIGHT OF 3-10 kDa
US12018087B2 (en)	2018-08-02	2024-06-25	Dyne Therapeutics, Inc.	Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en)	2018-08-02	2021-11-09	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20220193250A1 (en)	2018-08-02	2022-06-23	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP7611825B2 (ja)	2018-08-02	2025-01-10	ダインセラピューティクス，インコーポレーテッド	ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
IL326747A (en)	2018-11-02	2026-04-01	Biomarin Tech Bv	Bispecific antisense oligonucleotides for dystrophin exon skipping
CN113383078A (zh) *	2018-12-06	2021-09-10	波涛生命科学有限公司	寡核苷酸组合物及其方法
CN113660938A (zh) *	2019-01-30	2021-11-16	国立研究开发法人国立精神·神经医疗研究中心	核酸递送复合物
CA3137715A1 (en)	2019-04-25	2020-10-29	Avidity Biosciences, Inc.	Nucleic acid compositions and methods of multi-exon skipping
EP4079329A4 (en) *	2019-12-19	2024-04-17	Nippon Shinyaku Co., Ltd.	ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING
AU2021226089A1 (en) *	2020-02-28	2022-09-15	National Center Of Neurology And Psychiatry	Antisense nucleic acid inducing skipping of exon 51
CA3216839A1 (en)	2021-04-30	2022-11-03	Sarepta Therapeutics, Inc.	Treatment methods for muscular dystrophy
US11771776B2 (en)	2021-07-09	2023-10-03	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN117980006A (zh)	2021-07-09	2024-05-03	达因疗法公司	用于治疗肌养蛋白病的肌肉靶向复合物和制剂
US11969475B2 (en)	2021-07-09	2024-04-30	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en)	2021-07-09	2023-05-02	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
KR20240129006A (ko)	2021-12-27	2024-08-27	니뽄 신야쿠 가부시키가이샤	올리고 핵산 화합물의 제조 방법
CN120129745A (zh)	2022-03-10	2025-06-10	日本新药株式会社	抗病毒反义低聚物
JP2025509438A (ja)	2022-03-17	2025-04-11	サレプタセラピューティクス，インコーポレイテッド	ホスホロジアミデートモルホリノオリゴマーコンジュゲート
US12071621B2 (en)	2022-04-05	2024-08-27	Avidity Biosciences, Inc.	Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
EP0962463B1 (en)	1989-12-20	2002-07-10	Antivirals Inc.	Uncharged morpholino-based polymers having phosphorus-containing chiral intersubunit linkages
JP2924179B2 (ja)	1993-02-19	1999-07-26	日本新薬株式会社	グリセロール誘導体，デバイス及び医薬組成物
IL115849A0 (en)	1994-11-03	1996-01-31	Merz & Co Gmbh & Co	Tangential filtration preparation of liposomal drugs and liposome product thereof
EP1191097A1 (en)	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induction of exon skipping in eukaryotic cells
US7902160B2 (en)	2002-11-25	2011-03-08	Masafumi Matsuo	ENA nucleic acid drugs modifying splicing in mRNA precursor
PL1766010T3 (pl) *	2004-06-28	2011-07-29	Univ Western Australia	Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
JPWO2006038608A1 (ja)	2004-10-05	2008-05-15	日本新薬株式会社	オリゴ二本鎖ｒｎａ及び医薬組成物
US20090312532A1 (en) *	2005-04-22	2009-12-17	Van Deutekom Judith Christina	Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secodary rna structure
JP5056413B2 (ja)	2005-05-30	2012-10-24	日本新薬株式会社	核酸含有複合体製剤の製造方法
US8067571B2 (en) *	2005-07-13	2011-11-29	Avi Biopharma, Inc.	Antibacterial antisense oligonucleotide and method
RU2418068C2 (ru) *	2005-08-17	2011-05-10	Сирна Терапьютикс, Инк.	Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
EP1963538A2 (en) *	2005-11-30	2008-09-03	Guild Associates, Inc.	Differentially fluorescent yeast biosensors for the detection and biodegradation of chemical agents
WO2008096690A1 (ja)	2007-02-05	2008-08-14	Nippon Shinyaku Co., Ltd.	ポリエチレングリコール誘導体
EP2203173B1 (en)	2007-10-26	2015-12-23	Academisch Ziekenhuis Leiden	Means and methods for counteracting muscle disorders
DK2207779T3 (da)	2007-11-15	2014-07-14	Sarepta Therapeutics Inc	Fremgangsmåde til syntese af morpholinooligomerer
US8084601B2 (en)	2008-09-11	2011-12-27	Royal Holloway And Bedford New College Royal Holloway, University Of London	Oligomers
CN105779453A (zh)	2008-10-24	2016-07-20	萨雷普塔治疗公司	用于dmd的多外显子跳跃组合物
PT2344637E (pt)	2008-10-27	2015-03-23	Academisch Ziekenhuis Leiden	Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
US20110269665A1 (en)	2009-06-26	2011-11-03	Avi Biopharma, Inc.	Compound and method for treating myotonic dystrophy
BR122023023194A2 (pt) *	2009-11-12	2023-12-26	The University Of Western Australia	Oligonucleotídeo antissentido, composição e respectivo uso
KR102182663B1 (ko)	2010-05-28	2020-11-25	사렙타 쎄러퓨틱스, 인코퍼레이티드	변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
IT1400425B1 (it) *	2010-06-08	2013-05-31	Amsterdam Molecular Therapeutics Bv	Modified snrnas for use in therapy.
TWI541024B (zh) *	2010-09-01	2016-07-11	日本新藥股份有限公司	反義核酸
CA2826836A1 (en) *	2011-02-08	2012-08-16	The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center	Antisense oligonucleotides
IL273838B (en) *	2011-05-05	2022-09-01	Sarepta Therapeutics Inc	Peptide and oligonucleotide conjugates, preparations containing them and their uses
CA3132111A1 (en) *	2011-12-28	2013-07-04	Nippon Shinyaku Co., Ltd.	Antisense nucleic acids for skipping of exon 55 of human dystrophin gene
RU2730681C2 (ru) *	2014-03-12	2020-08-24	Ниппон Синяку Ко., Лтд.	Антисмысловые нуклеиновые кислоты

2015
- 2015-03-11 RU RU2019130513A patent/RU2730681C2/ru active
- 2015-03-11 JP JP2016507800A patent/JP6606488B2/ja active Active
- 2015-03-11 EP EP18205909.7A patent/EP3514234A1/en active Pending
- 2015-03-11 EP EP15761392.8A patent/EP3118311B1/en active Active
- 2015-03-11 MX MX2016011538A patent/MX2016011538A/es active IP Right Grant
- 2015-03-11 HU HUE15761392A patent/HUE042283T2/hu unknown
- 2015-03-11 PL PL15761392T patent/PL3118311T3/pl unknown
- 2015-03-11 UA UAA201610167A patent/UA120849C2/uk unknown
- 2015-03-11 SM SM20190169T patent/SMT201900169T1/it unknown
- 2015-03-11 CA CA2939948A patent/CA2939948A1/en active Pending
- 2015-03-11 TR TR2019/01939T patent/TR201901939T4/tr unknown
- 2015-03-11 SI SI201530597T patent/SI3118311T1/sl unknown
- 2015-03-11 TW TW108129128A patent/TW201945383A/zh unknown
- 2015-03-11 CN CN201580012727.4A patent/CN106459955B/zh active Active
- 2015-03-11 RS RS20190188A patent/RS58573B1/sr unknown
- 2015-03-11 AU AU2015227733A patent/AU2015227733B2/en active Active
- 2015-03-11 US US15/122,435 patent/US9988629B2/en active Active
- 2015-03-11 BR BR112016020618-5A patent/BR112016020618B1/pt active IP Right Grant
- 2015-03-11 KR KR1020167027723A patent/KR102335801B1/ko active Active
- 2015-03-11 PT PT15761392T patent/PT3118311T/pt unknown
- 2015-03-11 LT LTEP15761392.8T patent/LT3118311T/lt unknown
- 2015-03-11 SG SG11201607095RA patent/SG11201607095RA/en unknown
- 2015-03-11 CN CN201911163414.5A patent/CN110951732A/zh active Pending
- 2015-03-11 NZ NZ724836A patent/NZ724836A/en unknown
- 2015-03-11 TW TW104107708A patent/TWI672314B/zh active
- 2015-03-11 WO PCT/JP2015/057180 patent/WO2015137409A1/ja not_active Ceased
- 2015-03-11 HR HRP20190235TT patent/HRP20190235T1/hr unknown
- 2015-03-11 ES ES15761392T patent/ES2710802T3/es active Active
- 2015-03-11 RU RU2016139108A patent/RU2702424C2/ru active
- 2015-03-11 DK DK15761392.8T patent/DK3118311T3/en active
- 2015-03-11 MY MYPI2016703281A patent/MY193708A/en unknown
2016
- 2016-08-23 ZA ZA2016/05864A patent/ZA201605864B/en unknown
- 2016-09-06 IL IL247663A patent/IL247663B/en active IP Right Grant
- 2016-09-07 PH PH12016501761A patent/PH12016501761B1/en unknown
2018
- 2018-02-22 US US15/902,231 patent/US20180179538A1/en not_active Abandoned
2019
- 2019-02-12 CY CY20191100184T patent/CY1121322T1/el unknown
- 2019-06-11 US US16/437,130 patent/US11053497B2/en active Active
2020
- 2020-01-30 AU AU2020200679A patent/AU2020200679B2/en active Active
2021
- 2021-06-30 US US17/364,618 patent/US20220162604A1/en not_active Abandoned
2024
- 2024-11-19 US US18/951,766 patent/US20250145997A1/en active Pending

Also Published As

Publication number	Publication date
US20180179538A1 (en)	2018-06-28
BR112016020618B1 (pt)	2023-04-04
KR102335801B1 (ko)	2021-12-03
US20170067048A1 (en)	2017-03-09
US11053497B2 (en)	2021-07-06
WO2015137409A1 (ja)	2015-09-17
CN106459955B (zh)	2019-12-20
SI3118311T1 (sl)	2019-05-31
TW201540724A (zh)	2015-11-01
AU2020200679A1 (en)	2020-02-20
RU2016139108A3 (pl)	2018-08-06
SG11201607095RA (en)	2016-10-28
US20200149040A1 (en)	2020-05-14
EP3514234A1 (en)	2019-07-24
IL247663A0 (en)	2016-11-30
TWI672314B (zh)	2019-09-21
JPWO2015137409A1 (ja)	2017-04-06
PH12016501761A1 (en)	2016-11-07
JP6606488B2 (ja)	2019-11-13
PT3118311T (pt)	2019-02-15
DK3118311T3 (en)	2019-03-11
SMT201900169T1 (it)	2019-05-10
MX2016011538A (es)	2017-04-13
AU2015227733B2 (en)	2019-10-31
LT3118311T (lt)	2019-04-10
TW201945383A (zh)	2019-12-01
CN106459955A (zh)	2017-02-22
CY1121322T1 (el)	2020-05-29
RS58573B1 (sr)	2019-05-31
RU2016139108A (ru)	2018-04-13
RU2730681C2 (ru)	2020-08-24
US9988629B2 (en)	2018-06-05
AU2015227733A1 (en)	2016-10-20
RU2019130513A3 (pl)	2020-03-13
UA120849C2 (uk)	2020-02-25
CN110951732A (zh)	2020-04-03
EP3118311B1 (en)	2018-12-26
KR20160132056A (ko)	2016-11-16
TR201901939T4 (tr)	2019-03-21
PH12016501761B1 (en)	2016-11-07
RU2702424C2 (ru)	2019-10-08
HUE042283T2 (hu)	2019-06-28
HRP20190235T1 (hr)	2019-05-03
BR112016020618A2 (pt)	2017-08-15
MY193708A (en)	2022-10-26
BR112016020618A8 (pt)	2021-07-13
RU2019130513A (ru)	2019-10-10
NZ724836A (en)	2022-07-01
ZA201605864B (en)	2018-12-19
AU2020200679B2 (en)	2022-03-10
EP3118311A4 (en)	2017-10-11
EP3118311A1 (en)	2017-01-18
US20250145997A1 (en)	2025-05-08
US20220162604A1 (en)	2022-05-26
IL247663B (en)	2020-06-30
ES2710802T3 (es)	2019-04-26
CA2939948A1 (en)	2015-09-17

Publication	Publication Date	Title
DK3981437T3 (da)	2025-01-13	Nukleinsyrevacciner
HRP20190235T1 (hr)	2019-05-03	Antisensna nukleinska kiselina
HUE049405T2 (hu)	2020-09-28	Nukleáz-közvetített DNS-összeállítás
DK3183051T3 (da)	2020-06-02	Væske-til-luftmembranenergivekslere
DK3134402T3 (da)	2020-07-20	4-amino-imidazoquinolinforbindelser
DK3211743T3 (da)	2019-12-16	Ø-til-netværk-omskiftningsfremgangsmåde
DK3006072T3 (da)	2021-10-25	Karadgang
DK3222714T3 (da)	2019-12-09	Phytasemutanter
DK3119396T3 (da)	2021-05-31	Muscarinreceptoragonister
EP3286549A4 (en)	2019-04-17	BIOSENSOR
DK3094731T3 (da)	2019-08-05	Saccharidmodificerede nukleinsyremolekyler
EP3230438C0 (en)	2024-12-04	N-GLYCOSYLATION
EP3156789C0 (en)	2024-01-03	BIOSENSOR
DK3310450T3 (da)	2019-08-05	Olie-vand-separator
EP4011484C0 (en)	2025-09-24	CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK4242916T3 (da)	2025-12-15	Forstøver
DK3183340T3 (da)	2019-08-19	Termolabile exonukleaser
DE112015001664A5 (de)	2016-12-29	Betätigungsaktuator
EP3387414A4 (en)	2019-07-10	BIOSENSOR
DK3154703T3 (da)	2020-11-16	Fuldkappe-snekkecentrifuge
EP3371575A4 (en)	2019-06-26	BIOSENSOR
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
IL249254A0 (en)	2017-02-28	Gene expression system
DK3110439T3 (da)	2019-05-13	Pcsk9-vacciner
DE102014000623A8 (de)	2016-10-13	Halbhohlnietelement